Everett Capital Advisors (UK)’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Everett Capital Advisors (UK)’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-855,476	Closed	-$17.6M	–	30
2018 Q3	$22.8M	Buy	855,476 +73,209	+9%	+$2.39M	3.32%	13
2018 Q2	$29.5M	Buy	782,267 +231,094	+42%	+$8.84M	2.04%	12
2018 Q1	$18M	Buy	551,173 +250,773	+83%	+$11M	1.52%	28
2017 Q4	$14.6M	Buy	300,400 +96,400	+47%	+$4.88M	2.25%	20
2017 Q3	$11M	Buy	+204,000	New	+$12M	1.63%	21

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Everett Capital Advisors (UK)'s PTLA Position: Q4 2018 in Review

Everett Capital Advisors (UK) sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2018, closing a stake of 855,476 shares — an estimated $17.6M sold.

Everett Capital Advisors (UK) first reported a position in PTLA in Q3 2017 and held it in 5 quarters. The position peaked at $29.5M in Q2 2018. 181 funds tracked by Wall St. Rank hold PTLA as of Q4 2018.

Everett Capital Advisors (UK) reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Everett Capital Advisors (UK) sold 855,476 Portola Pharmaceuticals, Inc. shares in Q4 2018, an estimated $17.6M.
Everett Capital Advisors (UK) first reported a position in Portola Pharmaceuticals, Inc. in Q3 2017 and held it in 5 quarters.
Everett Capital Advisors (UK)'s Portola Pharmaceuticals, Inc. position peaked at $29.5M in Q2 2018.
181 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2018.

Based on Everett Capital Advisors (UK)'s 13F filing for Q4 2018, filed 13 Feb 2019.